SAB Biotherapeutics (SABS) Non-Current Deffered Revenue (2021)
SAB Biotherapeutics (SABS) reported Non-Current Deffered Revenue of -$4.2 million for Q3 2021, little changed quarter-over-quarter from -$4.2 million in Q2 2021.
SAB Biotherapeutics (SABS) Non-Current Deffered Revenue (2021) Analysis & Trends
SAB Biotherapeutics has reported Non-Current Deffered Revenue for 1 years, with the latest figure at -$4.2 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | -4.22 Mn |
| Jun 30, 2021 | -4.22 Mn |
| Mar 31, 2021 | 4.22 Mn |